Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rohto Pharmaceutical CoRPHCF 91 Earnings Yield (Joel Greenblatt) % is 8.98% as of Mar. 2026, which is 39% above its 10-year median of 6.44. GuruFocus rates RPHCF with a GF Score™ of 91/100 and a GF Value™ of $22.21. The stock has 2 warning signs investors should review. Among 2,033 Consumer Packaged Goods companies, Rohto Pharmaceutical Co ranks better than 66.06% on this metric.
Rohto Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2026 was $3,383 Mil.
Rohto Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $318 Mil. Rohto Pharmaceutical Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 8.98%.
The historical rank and industry rank for Rohto Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
RPHCF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.15 Med: 6.44 Max: 10.04
Current: 9.2
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Rohto Pharmaceutical Co was 10.04%. The lowest was 4.15%. And the median was 6.44%.
RPHCF's Earnings Yield (Joel Greenblatt) % is ranked better than 66.06% of 2033
companies
in the Consumer Packaged Goods industry
Industry Median: 6.03
vs RPHCF: 9.20
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Rohto Pharmaceutical Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 19.89%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Rohto Pharmaceutical Co (OTCPK:RPHCF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Rohto Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Related Terms
Rohto Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Rohto Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rohto Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Chart
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co Earnings Yield (Joel Greenblatt) % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % falls into.
Rohto Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Rohto Pharmaceutical Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
Rohto Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $318 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 8.98% mean?
Rohto Pharmaceutical Co (RPHCF) has a Earnings Yield (Joel Greenblatt) % of 8.98% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Rohto Pharmaceutical Co and its competitors. This is 39% above median its historical median of 6.44. Over the past decade, Rohto Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % has ranged from 4.15 to 10.04. According to the industry distribution chart, Rohto Pharmaceutical Co ranks #690 out of 2033 companies in the Consumer Packaged Goods industry, placing it in the top 33.9%.
Is Rohto Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % too high?
Rohto Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % of 8.98% is 39% above median its 10-year median of 6.44. Over the past 10 years, this metric has ranged from a low of 4.15 to a high of 10.04. The Consumer Packaged Goods industry median Earnings Yield (Joel Greenblatt) % is 6.03. Rohto Pharmaceutical Co's value of 8.98% is 48.9% above this industry median. Based on the distribution chart, Rohto Pharmaceutical Co ranks #690 out of 2033 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Rohto Pharmaceutical Co has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Rohto Pharmaceutical Co ranks #690 out of 2033 companies for Earnings Yield (Joel Greenblatt) %. This puts Rohto Pharmaceutical Co in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 6.03. Rohto Pharmaceutical Co's value of 8.98% is 48.9% above this benchmark. Historically, Rohto Pharmaceutical Co's own Earnings Yield (Joel Greenblatt) % has ranged from 4.15 to 10.04 over the past decade. While the company's 10-year median is 6.44 vs. the industry median of 6.03, Rohto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median Earnings Yield (Joel Greenblatt) % among Consumer Packaged Goods companies is 6.03, based on 2,033 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rohto Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % of 8.98% is 48.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Rohto Pharmaceutical Co and its competitors. For the Consumer Packaged Goods industry, the median Earnings Yield (Joel Greenblatt) % is 6.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rohto Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % is 8.98%, which is 39% above median its own 10-year median of 6.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Rohto Pharmaceutical Co (RPHCF) has a current Earnings Yield (Joel Greenblatt) % of 8.98%. The stock's GF Value™ is $22.21, compared to a current price of $15.00 — trading 32.5% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 8.98%, which is 39% above median its 10-year median of 6.44 and 48.9% above the Consumer Packaged Goods industry median of 6.03. Rohto Pharmaceutical Co's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Rohto Pharmaceutical Co (RPHCF), the current Earnings Yield (Joel Greenblatt) % is 8.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rohto Pharmaceutical Co (RPHCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of $15.00 is trading 32.5% below its estimated GF Value™ of $22.21.
Key valuation signals for RPHCF:
Earnings Yield (Joel Greenblatt) %: 8.98% (39% above median its 10-year median of 6.44)
GF Value™: $22.21 vs. price of $15.00 (32.5% below fair value)
Industry Position: 48.9% above the Consumer Packaged Goods median (#690 of 2033)
No single metric tells the full story. See the RPHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
91GF Score
Get the complete analysis for RPHCF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPHCF has been successfully added to your 
